Genetic Toxicity Testing Services for the NTP

NTP 基因毒性测试服务

• 批准号: 9287915
• 负责人: LES RECIO
• 金额: $ 94.35万
• 依托单位: INTEGRATED LABORATORY SYSTEMS, LLC
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-09-19 至 2017-06-05
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9287915
• 关键词: Aging; Anabolism; Animal Model; Animal Testing; Animals; Autistic Disorder; Biological Assay; Biological Monitoring; Blood specimen; Botanicals; Brain; Cancer Etiology; Cells; Chemicals; Clinical; Clinical Research; Collaborations; Comet Assay; Congenital Abnormality; Contracts; DNA Damage; Data; Data Set; Disease; Down Syndrome; Environmental Exposure; Erythrocytes; Event; Exposure to; Family suidae; Food Additives; Frequencies; Future; Genes; Genetic; Goals; Guidelines; Health; Human; In Vitro; International; Investigation; Kidney; Laboratories; Leadership; Liver; Lung; Methods; Micronucleus Tests; Mission; Mitochondrial Diseases; Molecular; Mus; Mutagenicity Tests; Mutation; National Institute of Environmental Health Sciences; Neurodegenerative Disorders; Neurologic; Outcome; PI-Glycan; Pharmaceutical Preparations; Population; Protocols documentation; Rattus; Research Personnel; Rodent; Sampling; Services; Source; Stomach; Support System; System; Testing; Tissues; Toxic effect; Toxicity Tests; Toxicogenetics; Translating; Translations; Update; Woman; base; cancer genetics; cancer risk; carcinogenicity; cost; environmental agent; exposed human population; genetic profiling; genotoxicity; hazard; human study; in vivo; innovation; insight; interest; micronucleus; peripheral blood; pollutant

This genetic toxicology testing contract has supported the overall mission of NTP to provide detailed toxicological profiles, including potential for carcinogenicity, of compounds of interest for 30 years. Assessment of genetic damage, an important factor in the etiology of cancer as well as neurodegenerative diseases such as ALS, neurological conditions such as autism, aging, birth defects such as Down syndrome, mitochondrial diseases, and other adverse human health effects, is a critical component of any in-depth toxicological profile of a chemical or product. This Genetic Toxicity Testing contract provides information on exposure-related genetic damage to NTP using standard tests as well as innovative protocols when necessary. The capabilities of the contract are continuously updated to remain current and compatible with international guidelines for conducting these kinds of tests. Testing systems employed include both in vitro (animal cell-based and bacterial) and in vivo (rats and mice) assays. In vivo studies using human blood samples can also be conducted to translate findings from animal studies to human exposure scenarios. Three main tests are conducted routinely: in vitro bacterial mutagenicity assays, in vivo rodent peripheral blood micronucleus (MN) assays, and in vivo rodent DNA damage (Comet) assays in multiple tissues including, for example, liver, brain, stomach, kidney, and lung. Using peripheral blood as the sample source, MN and Comet studies can also be conducted in humans. In addition, in vitro MN assays have become increasingly used as a substitute for stand-alone in vivo rodent MN assays. An animal mutation endpoint that holds promise for application in human clinical and biomonitoring studies in the future, has been investigated in the testing laboratory: the pig-a mutation assay (phosphatidylinositol glycan anchor biosynthesis, class A gene). Mutations in this gene are easily detected in red blood cell samples from laboratory rodents, and updated methods to streamline the assay have been developed, so that integration into existing toxicity tests can easily be accomplished. In future studies we plan to multiplex this assay with the in vivo MN and Comet assays, increasing the genetic damage information we obtain from test animals to provide an even more comprehensive profile of the genetic toxicity potential of a chemical. In addition to our cell-based and animal model studies, human blood samples provided by collaborators such as NIOSH and the NIEHS Clinical Research Unit may also be examined for specific genetic endpoints following an environmental exposure that is suspected of inducing genetic damage, or has been shown to do so in NTP animal studies. The number of studies of each type described above varies annually, depending on the needs of the NTP. For example, this past year, the NTP genetic toxicity testing laboratory conducted innovative in vitro chromosomal damage studies with 14 cohosh samples (botanical products) to provide mechanistic information to support the previously observed induction of MN in rats and mice, and to provide insight into the NTP’s MN investigations that are currently ongoing in women who are using this product. These tests were in addition to the usual number of studies planned annually.

这种遗传性毒理学测试已支持提供详细的毒理学特征R c癌性，这是30年30年的兴趣。生成疾病，例如ASALS，例如自闭症等神经病学疾病，唐氏综合症，线粒体diseason TS，是任何关键的组成部分该遗传测试合同的深入毒理学概况使用的是体外（大鼠和小鼠）在体内研究中，也可以在体内进行体内研究。细菌性毒品的攻击问题，包括肝脏，大脑，胃，肾脏和肺部。代替独立的n Vivo啮齿动物MN分析。从实验室啮齿动物和更新的方法中，可以轻松地将突击集成到现有测试中。合作者和NIEHS临床研究单位提供的D型样品的遗传毒素潜力也可以检查特定的遗传学终点，该终点是避免遗传损害的野蛮人，或者已在NTP动物研究中证明是这样做的。上面描述的是每年不同的，具体取决于NTP的需求。目前，这些测试的妇女正在进行中。